Trial of satralizumab in neuromyelitis optica spectrum disorder

New England Journal of Medicine

Volumn 381, Issue 22, 2019, Pages 2114-2124

  Yamamura, T ^a   Kleiter, I ^d,e   Fujihara, K ^c   Palace, J ^f   Greenberg, B ^h   Zakrzewska Pniewska, B ⁱ   Patti, F ^j   Tsai, C P ^k   Saiz, A ^l   Yamazaki, H ^b   Kawata, Y ^b   Wright, P ^g   De Seze, J ^m,n  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b Chugai Pharmaceutical   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d ST JOSEF HOSPITAL   (Germany)

^e Marianne Strauss Hospital   (Germany)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^g United Kingdom Safeguards Office   (United Kingdom)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ MEDICAL UNIVERSITY OF WARSAW   (Poland)

^j UNIVERSITY OF CATANIA   (Italy)

^k NATIONAL YANG MING UNIVERSITY   (Taiwan)

^l UNIVERSITY OF BARCELONA   (Spain)

^m HÔPITAL DE HAUTEPIERRE   (France)

ⁿ Ecole Supérieure de Biotechnologie   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; IMMUNOGLOBULIN G; PLACEBO; SATRALIZUMAB; AQUAPORIN 4; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOOPTIC NEUROPATHY; NEOPLASM; PAIN ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SERODIAGNOSIS; TREATMENT DURATION; VISUAL ANALOG SCALE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUAPORIN 4; AUTOANTIBODIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; RECEPTORS, INTERLEUKIN-6; RECURRENCE; YOUNG ADULT;

EID: 85075751523     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1901747     Document Type: Article

References (28)

1. Oh J, Levy M. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int 2012; 2012: 460825.
2. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-89.
3. Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc 2017; 92: 663-79.
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-15.
5. Lemos MD, Carvalho GB, Carvalho RS, Bichuetti DB, de Oliveira EM, Abdala N. Neuromyelitis optica spectrum disorders: beyond longitudinally extensive transverse myelitis. Clin Radiol 2015; 70: 630-7.
6. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135: 1834-49.
7. Seok JM, Cho EB, Lee HL, et al. Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2016; 368: 209-13.
8. Kanamori Y, Nakashima I, Takai Y, et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology 2011; 77: 652-8.
9. Akaishi T, Nakashima I, Misu T, Fujihara K, Aoki M. Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica. J Neuroimmunol 2015; 283: 70-3.
10. Kowarik MC, Soltys J, Bennett JL. The treatment of neuromyelitis optica. J Neuroophthalmol 2014; 34: 70-82.
11. Sepúlveda M, Armangué T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 2016; 3(3): e225.
12. Nagelhus EA, Ottersen OP. Physiological roles of aquaporin-4 in brain. Physiol Rev 2013; 93: 1543-62.
13. Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol 2014; 10: 493-506.
14. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010; 16: 1443-52.
15. Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol 2016; 183: 480-9.
16. Matsushita T, Tateishi T, Isobe N, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 2013; 8(4): e61835.
17. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830-5.
18. Lin J, Li X, Xia J. Th17 cells in neuromyelitis optica spectrum disorder: a review. Int J Neurosci 2016; 126: 1051-60.
19. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes antiaquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011; 108: 3701-6.
20. Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 2016; 13: 70-83.
21. Reichert JM. Antibodies to watch in 2017. MAbs 2017; 9: 167-81.
22. Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford) 2018; 57: Suppl 2: ii43-ii50.
23. Igawa T, Ishii S, Tachibana T, et al. Antibody recycling by engineered pHdependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28: 1203-7.
24. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-9.
25. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1: 79.
26. Hsu CH, Taylor JM. Nonparametric comparison of two survival functions with dependent censoring via nonparametric multiple imputation. Stat Med 2009; 28: 462-75.
27. Jackson D, White IR, Seaman S, Evans H, Baisley K, Carpenter J. Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputation. Stat Med 2014; 33: 4681-94.
28. Lipkovich I, Ratitch B, O'Kelly M. Sensitivity to censored-at-random assumption in the analysis of time-to-event endpoints. Pharm Stat 2016; 15: 216-29.